Erlocip 150mg

Erlocip 150mg tablets consist of active ingredients known as Erlotinib (Generic Tarceva), that is considered as quinazoline derivative and anti-cancer agents that responses as a protein kinase prohibition for EGFR related to tyrosine kinase. Erlocip is majorly used in the treatment of non-small cell lung cancer and pancreatic carcinoma and also involved to treat various cancers. Erlocip has especially aimed at the epidermal growth factor receptor tyrosine kinase.

USES OF Erlocip

Nonsmall cell lung cancer:

Erlocip 150mg is indicated as continuance therapy, in patients with long-lasting or metastasis non-small cell lung carcinoma, whose disease has not to get advance after four cycles with platinum-based first-line therapy. Erlocip is used in this condition only after the failure of one prior chemotherapy regimen. No clinical advantages occur while using Erlocip with platinum-based compounds like Carboplatin, gemcitabine or cisplatin.
Pancreatic cancer:

Erlocip 150mg (Erlotinib Hydrochloride) is indicated for the treatment concurrently with gemcitabine, gemcitabine is a chemotherapy drug used to treat the cancer of the ovary, breast, pancreas, bladder and nonsmall cell lung cancer. Cisplatin is also a chemotherapic drug used for the treatment of various types of cancer.

Erlocip 150mg,Erlocip 150mg tablet

Erlotinib mechanism of action

The mechanism of clinical action of erlotinib is not fully revealed/characterized, Erlocip has pharmacological effects like anti-neoplastic activity, which exhibits its action by inhibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is present on the surface of the tumor cells, the main ingredient which is used as erlotinib. Thus results as inhibition causes interfere with signal transduction and lead to cell lysis.
In case of patients suffered from pulmonary symptoms like dyspnea, fever, cough, or any other conditions, Erlocip treatment should be discontinued. In interstitial lung disease: To avoid the Erlocip 150mg therapy. In case of gastrointestinal perforation or hepatic failure: Postpone or discontinue the Erlocip treatment. If diarrhea occurs during the therapy, substitute with loperamide for managing this condition. If dosage reduction is necessary then the dose of Erlocip 150mg reduced into 50mg. Dose reduction is essential in the condition, while concomitant of Erlocip 150mg with strong CYP3A4 inhibitors like atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, voriconazole, grapefruit juice, etc. Dosage elevation occurs in case of concurrent use of Erlocip with strong CYP3A4 inducers like rifampin, rifampicin, anti-convulsants, etc. The dosage should be increased by 50mg. In chain smoking conditions, increase the Erlotinib dose into 50mg at two intervals to a higher dose of 300mg. Then the dose is suddenly reduced to 100mg or 150mg in discontinuation of smoking. Erlocip should not be administered with gastric regulators drug, like proton pump inhibitors or H2 receptor antagonist. In H2 receptors antagonist: Administer Erlocip at least 10 hours after or 2 hours before H2 receptors antagonist. In proton pump inhibitors: Do not use concurrently if possible.

PHARMACOKINETICS

The peak plasma concentration-time reaches at 4 hours after drug intake After an oral administration of Erlocip 150mg, causes 60% of oral bioavailability. Increased by meals to 100%. The solubility of Erlotinib is depended upon pH level. If solubility decreases then lead to increase pH levels. Smoking should be avoided during the treatment with Erlocip, causes decreasing the exposure of Erlotinib. The apparent volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%. The metabolism of Erlotinib is occurred by CYP3A4 The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% half-life period of Erlotinib is 36.2 hours.

DOSAGE AND ADMINISTRATION

In NSCLC:

The usual recommended dosage of Erlocip 150mg should be administered as a single dose by taking in an empty stomach for at least one hour earlier or two hours after intake of food. Therapy with Erlocip should be continued until the disease advanced or undesirable toxicity occurs. It is not confirmed that advancement after the therapy is beneficial or not.

In pancreatic cancer:

The daily usual recommended dosage of Erlocip in pancreatic carcinoma is 100mg should be taken on an empty stomach as a single dose. In this condition, Erlocip is combined with gemcitabine.

WARNING AND PRECAUTIONS

Pulmonary toxicity: 

Interstitial lung disease and other pulmonary toxicity conditions, Avoid the treatment with Erlocip 150mg Renal failure: Frequent monitoring of renal function or serum electrolytes occurs or avoids the treatment. Bullous & exfoliative skin disorders Myocardial infarction or Ischemia Cerebrovascular accident Ocular disorder Elevation of bleeding while concurrent use with warfarin Hemolytic anemia or thrombocytopenia In pregnancy condition In all these conditions, treatment using with Erlocip should be avoided. Hepatic failure: Hepatic function should be periodically monitored, or otherwise discontinue the therapy with Erlocip. Gastrointestinal perforation: In this condition, discontinue the Erlocip therapy permanently. This condition occurs due to concurrent use of Erlocip with NSAIDS, anti-angiogenic drugs, corticosteroids, taxane-based chemotherapy or other drugs, etc.

SOME INTERACTION WITH SOME OTHER DRUGS

Co-administration of Erlocip 150mg tablet with midazolam causes decreasing the AUC of CYP3A4 substrate. Drugs involved in alteration of pH levels causes variation in the solubility of Erlotinib. Avoid concomitant use of gastric regulators with Erlocip 150mg tablet. Avoid concomitant use of warfarin with Erlocip, causes increasing the bleeding condition. Co-administration of Erlocip with CYP3A4 strong inhibitors like ketoconazole causes increasing Erlotinib exposure. Erlocip concomitant with statins drugs (lipid-lowering drug), causes increasing the concentration of these drugs (rosuvastatin, simvastatin or atorvastatin). Erlocip concurrently used with ciprofloxacin, CYP3A4 & CYP1A2 inhibitor causes elevation of exposure of Erlocip 150mg tablets. CYP3A4 strong inhibitors like itraconazole, grapefruit juice, ritonavir, indinavir, etc CYP3A4 inducers concurrently used with Erlocip tablets causes decreasing the exposure of Erlocip 150mg tablet. CYP3A4inducers like, rifampin, rifampicin, carbamazepine, phenytoin, etc Cigarette smoking is decreasing the AUC of Erlotinib.

ERLOTINIB SIDE EFFECTS

During the therapy, some undesirable effects like; Paronychia, Bullous, blistering and exploitative skin conditions like Stevens Johnson’s syndrome. Gastrointestinal perforation Hepatic failure occurs during monotherapy or combination with other chemotherapy agents Some common side effects of Erlotinib are Diarrhea, Fatigue, Anorexia, Pruritus, Acne, Dermatitis, Dry skin, Loss of weight, Paronychia, Cough, Vomiting, Conjunctivitis, Keratoconjunctivitis sicca, Abdominal pain, Stomatitis, Infection, nausea, Bone pain, Alopecia, Anxiety, Neuropathy, Renal disorders, hepatic disorders, ocular disorders, skin, hair and nail disorders

OVERDOSAGE

In case of overdosage, Erlocip150mg therapy should be postponed and symptomatic treatment should be recommended.

CONTRAINDICATION

In Erlocip 150mg therapy, no contraindication occurs. In some patients, hypersensitivity reactions present due to patients are contraindicated to the ingredients in Erlocip.

Contact Details

Phone : +91-9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com